Gail Page

BOARD MEMBER

  • 30+ years in life sciences

  • Executive management roles with LabCorp, Roche Biomedical, Luminex and Vermillion, Inc.

  • Venture Partner at Turret Capital Management

Ms. Page has more than 30 years of life sciences experience, and currently serves as Managing Partner of pH Blueprint, a strategic advisory firm focused on collaborating with medical device, diagnostics, and biotech clients. She is also a Venture Partner at Turret Capital Management, a global healthcare investment and venture firm. Previously Ms. Page served in executive management roles with LabCorp and Roche Biomedical, and as Chief Operating Officer at Luminex.

Prior to these ventures, Ms. Page served as the President / CEO of Vermillion, Inc. from Jan 2004 thru December 2012. She was a member of the board from 2006 thru 2012 and served as Chairperson from 2010-2011. The focus of Vermillion was on developing and commercializing novel multiproteomic/IVDMIA blood test. Upon joining Vermillion in 2004 she inspired a pioneering spirit. Under her leadership the company was repositioned to embrace the progressive nature of its pipeline, successfully raised over $100M in funding, developed and commercially launched the first FDA-cleared blood test to help diagnose ovarian cancer by engaging Quest Diagnostics as an equity and commercial partner.  In January 2020, she served as the Interim CEO of Chembio successfully creating a pivot and lead a $30M capital raise Ms. Page has spent her entire career in health care and has a passion for emerging technologies that advance the efforts in personalized medicine and wellness.

Her current and past board appointments include public and private companies. Her current board appointments include Sword Diagnostics, Inc. Mellitus,LLC and NxPrenatal, Inc. where she serves as Executive Chair.  From July 2017 thru July 2020, she served on the Chembio (CEMI NASDAQ) board and was Chair of the Compensation Committee and a member of the Audit Committee and Governance Committee. Most recently, she was appointed to the Advisory Board of Nexxus ( affiliated with the University Texas) and is a strategic advisor to Chosen Diagnostics.